Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Edgewise Therapeutics, Inc. terminated Prior Sales Agreement with Cowen and Company, LLC valued at Terminated prior to any sales of Placement Shares (effective 2023-06-15).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Cowen and Company, LLC
- Value
- Terminated prior to any sales of Placement Shares
- Effective
- 2023-06-15
Exact text from the filing
In connection with the Company’s entry into the Sales Agreement, on June 15, 2023, the Company delivered written notice to Cowen to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Edgewise Therapeutics, Inc. entered into Sales Agreement with BofA Securities, Inc. valued at up to $125,000,000 (effective 2023-06-16).
- Action
- entry
- Agreement
- atm program
- Counterparty
- BofA Securities, Inc.
- Value
- up to $125,000,000
- Effective
- 2023-06-16
Exact text from the filing
On June 16, 2023, Edgewise Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc. (“BofA Securities”) under which the Company may offer and sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having aggregate sales proceeds of up to $125,000,000 (the “Shares”), from time to time, through an “at the market offering” program under which BofA Securities will act as sales agent.
View on SEC.gov